Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma

P van der Ploeg^{a,*}, W Verhaegh^b, J de Hullu^c, A van de Stolpe^b, JMJ Piek^a

^a Catharina Hospital Eindhoven, Eindhoven, The Netherlands ^b Philips Research, Eindhoven, The Netherlands

Introduction

High-grade serous (ovarian) carcinoma (HGSC) is the most lethal gynaecological malignancy with a 5-year survival rate of approximately 30%¹. Knowledge on the cellular processes in carcinogenesis, such as signal transduction pathways (STPs), is needed for the development of targeted therapies². One such STP is the hedgehog (HH) pathway and previous research yielded contradictory results on HH activity in HGSC³. As most HGSC are thought to arise from Fallopian tube epithelium (FTE), the aim of our study was to determine the *functional* HH activity in HGSC and Fallopian tube stem cells (FTSC) compared to normal FTE, in order to provide new insights in the HGSC cell type of origin and the potential use of HH targeted therapies.




Figure 1. Overview of the personalized cancer treatment with targeted therapy.

Figure 2. Overview of important signal transduction pathways that drive tumour growth and some therapeutic options.


Methods


We used a computational diagnostic approach, signal transduction pathway activation (STA) analysis, enabling quantitative measurements of the *functional* pathway activity using Bayesian networks that look at mRNA levels of pathway target genes resulting from activation⁴. STA-analysis was performed on publicly available Affymetrix data (GSE28044, GSE9891 and GSE69428) containing microdissected normal FTE (n=22), HGSC (n=150) and cultured FTSC (n=2)⁵⁻⁷.

- 2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
- 3. Chen Q, Gao G, Luo S. Hedgehog signaling pathway and ovarian cancer. Chin J Cancer Res. 2013;25(3):346-53

4. Verhaegh W. et al. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 2014;74(11):2936-45.

^c Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands Corresponding author at: phyllis.vd.ploeg@catharinaziekenhuis.nl






5. Yamamoto Y, et al. In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells. J Pathol. 2016:238(4):519-30. 6. George SH. et al. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol. 2011;225(1):106-17. 7. Tothill RW. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-208 8. Paik. et al. Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem Cells. 2012 Nov; 30(11): 2487–2497.

Department of Gynecology and Obstetrics

Results

Figure 5. Survival plot illustrating high (HH score > 45) and low (HH score \leq 45) HH activity in 138 highgrade serous carcinomas (HGSC) with overall survival (months) (p = 0.029).



Conclusions

With the use of STA-analysis we showed significant higher *functional* HH activity in HGSC and FTSC compared to normal FTE, suggesting that the HH STP has a tumour-promoting role in HGSC. We indicated 47% of the HGSC as highly HH active and correlated this to poor survival. We suggest that the HH active subpopulation of HGSC might be of interest for HH targeted therapies.

Project in collaboration with:

PHILIPS





We demonstrated **higher** *functional* **HH** activity in **HGSC** (p < 0.001) and FTSC (p = 0.022) compared to normal FTE (Figure 4). HH activity in HGSC and FTSC were comparable, supporting the hypothesis of FTSC as the cell type of origin of HGSC. This is in agreement with earlier findings of Fallopian tube stem-like cells in cancerous lesions in the distal fimbriae⁸. We considered 47% of HGSC as highly HH active and correlated this to poor overall survival (p = 0.029) (Figure 5).









References 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30